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Since they were first described as cytosolic sensors of microbial molecules a decade ago,
the Nod-like receptors (NLRs) have been shown to have many different and important
roles in various aspects of immune and inflammatory responses, ranging from antimi-
crobial mechanisms to control of adaptive responses. In this review, we focus on the
interplay between NLRs and autophagy, an evolutionarily conserved mechanism that is
crucial for homeostasis and has recently been shown to be involved in the protective
response against infections. Furthermore, the association between mutations of NLRs as
well as proteins that form the autophagic machinery and inflammatory diseases such as
Crohn’s disease highlight the importance of these proteins and their interactions in the
regulation of inflammation.
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INTRODUCTION
Homeostasis in multicellular organisms is dependent on the abil-
ity to detect and adapt to a myriad of environmental variations
and insults, including exposure to microbes. Early detection of
microbes is a crucial step in the defense strategy. Through-
out evolution, the continuous interplay between multicellular
organisms and microbes has led to the selection of sensors that
allow early detection and initiation of the immune response
against infections. This detection is based on the recognition of
“microbial-associated molecular patterns” (MAMPs), which rep-
resent a signature of microbial origin, such as lipopolysaccharide
(LPS), peptidoglycan (PG), flagellin, and nucleic acids from bac-
teria and viruses, or of “danger-associated molecular patterns”
(DAMPs), which indicate the existence of cellular damage, such
as extracellular ATP and HGMB1 by “pattern recognition mole-
cules”(PRMs). Upon activation, PRMs trigger several protective
responses that include the recruitment of phagocytic cells; secre-
tion of chemokines, cytokines, and antimicrobial peptides; and
priming of dendritic cells (DCs), engaging the adaptive immune
system. Several families of PRMs have been described and include
“Toll-like receptors” (TLRs), “RIG-I like receptors” (RLRs), “C-
lectin type like receptors”(CLR), and“Nod-like receptors”(NLRs).
In addition to their role in innate and adaptive immune responses,
all of them have been recently implicated in the control of
autophagy, an adaptive cellular response to environmental and
microbial-induced stress. In this review, we highlight the role of
NLR signaling in the control of autophagy and vice versa, the
mechanisms involved and implications for inflammatory diseases
such as Crohn’s disease (CD) and type 2 diabetes (T2D).
NLR PROTEINS
Soon after the discovery of the transmembrane TLRs, it became
evident that additional sensors were necessary for the surveillance
of the cytosol. More than a decade ago, the demonstration that
a mammalian homolog of plant disease-resistance (R) proteins
called Nod1 could detect the presence of intracellular Shigella
flexneri and activate the transcription factor nuclear factorκB (NF-
κB) in epithelial cells in vitro inaugurated the studies on the role
of NLRs as innate immune intracellular sensors (1). Subsequent
studies have now set the number of human NLRs at approximately
20 and indicated their involvement in detecting not only micro-
bial components but also DAMPs such as ATP, mitochondrial DNA
(mtDNA) and reactive oxygen species (ROS) (2).
Due to the lack of signal peptides or transmembrane domains
in their amino acid sequences, NLRs are thought to be exclu-
sively located inside the cell. Both plant and animal NLRs are
signal-transduction ATPases with numerous domains (STAND)
P-loop ATPases of the AAA+ superfamily. The typical NLR pro-
tein contains the following domains: (a) a C-terminal leucine-rich
repeat (LRR) domain, involved in sensing; (b) a central NATCH
[Naip, CIITA, HET-E (plant het product involved in vegetative
incompatibility)] and TP-1 (telomerase-associated protein 1 that
mediates self-oligomerization and is essential for activation of
NLRs); and (c) an N-terminal effector domain, responsible for
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protein–protein interactions with adapter molecules and signal
transduction. Based on the nature of the N-terminal domains,
NLRs have been separated into the NLRC subfamily, containing
a CARD domain (caspase activation and recruitment domain);
the NLRP subfamily, containing a pyrin domain; and the NAIP
subfamily, which includes three (BIRs) baculovirus inhibitors of
the apoptosis protein repeat domain (3).
Nod1 (NLRC1) AND Nod2 (NLRC2) ARE INTRACELLULAR
PEPTIDOGLYCAN SENSORS
Nod1 and Nod2 were the first NLRs identified as MAMP detec-
tors when two concomitant studies demonstrated that Nod2
detects muramyl-dipeptide (MDP), a common motif found
in Gram-negative and Gram-positive PG and a major com-
ponent of adjuvants (1, 4–6). Nod1, in contrast, recognizes
PG containing the minimal motif meso-diaminopimelic acid
(DAP), an amino acid found in Gram-negative and some Gram-
positive bacteria, such as Listeria monocytogenes and Bacillus
subtilis. The naturally occurring PG moieties sensed by human
and mouse Nod1 are GlcNAc-MurNAc-l-Ala-d-Glu-meso-DAP
(GM-triDAP) and GlcNAc-MurNAc-l-Ala-d-Glu-meso-DAP-d-
Ala (GM-tetraDAP), respectively. After additional studies demon-
strated that PG recognition by TLR2 was due to contaminants
commonly found in PG preparations, it became clear that Nod1
and Nod2 are the only known PG sensors (2, 7–9). The NLR
ligands/activators are summarized in Table 1.
Nod1 and Nod2 have been implicated in the detection of a
vast array of microbial pathogens including bacteria, parasites,
and viruses. A key role for Nod1 and Nod2 in the detection of
bacterial infection has been demonstrated in Helicobacter pylori,
Escherichia coli, Chlamydia spp., Campylobacter jejuni, Salmo-
nella spp., Pseudomonas aeruginosa, S. flexneri, and L. monocyto-
genes, Mycobacterium tuberculosis, and Streptococcus pneumoniae
(Table 1).
More recent studies have uncovered surprising data regarding
microbial recognition by Nod1 and Nod2. Nod1-deficient mice are
more susceptible to infection with Trypanosoma cruzi, the etiolog-
ical agent of Chagas disease, apparently due to the lack of a robust
nitric oxide production, suggesting that Nod1 may be involved
in PG-independent microbial sensing given that T. cruzi does not
express PG (3, 28).
Supporting a role for Nod2 in the control of infections beyond
bacterial/PG detection, Shaw et al. using a Toxoplasma gondii infec-
tion model, described a T cell intrinsic role in Nod2-deficient
mice and a consequent Th1-defective immune response. In their
experiments, the authors observed lower amounts of IL-2 not only
during infection with T. gondii but also following anti-CD28 lig-
ation. Despite the novelty of these results, T cell activation in
different models appears to be normal in Nod2-deficient mice
(75, 76).
Nod2 has also been implicated in the immune response to
viruses. In a recent study, Sabbah et al. demonstrated that Nod2
mediated the in vitro production of type I IFN in cells stimulated
with single stranded RNA (ssRNA) or infected with various RNA
viruses. These results support the observation, made in the same
study, that Nod2-deficient mice are more susceptible to respiratory
syncytial virus (RSV) (29).
Finally, both Nod1 and Nod2 have been implicated in inflam-
matory disorders because mutations in the genes that encode
these proteins were shown to be related to the establishment of
genetic inflammatory diseases. The first piece of evidence of a link
between mutations in NOD2 and CD [an inflammatory bowel
disease (IBD)] was provided by Hugot et al. which identified three
single nucleotide polymorphisms (SNPs) in the IBD1 locus associ-
ated with increased risk for CD (77). One of these SNPs, Leu1007fs,
is the most common Nod2 mutation associated with the disease
and encodes a protein that is no longer able to sense MDP or
localize to the plasma membrane as the normal protein does upon
activation (4, 78).
INFLAMMASOMES
By definition, inflammasomes are multimeric protein complexes
that comprise a “sensor NLR” and function as platforms for the
activation of pro-caspase-1, resulting in the processing of IL-1β
and IL-18 and their unconventional secretion (6, 79). Several
inflammasomes have been described so far, and among them, the
best studied are the ones that contain NLRP3 (formerly known as
NALP3) or NLRC4 (formerly known as IPAF). Many NLRs, such
as NLRP1, NLRP3, and NLRC4, use the adaptor protein apoptosis-
associated speck-like protein containing a CARD (ASC) to recruit
pro-caspase-1, but this does not apply to all inflammasomes.
NLRP3 INFLAMMASOMES
NLRP3 is mostly expressed in myeloid cells and is activated by a
vast array of host-derived and exogenous agonists. One common
feature of NLRP3 agonists seems to be a crystalline or polymeric
structure associated with danger signals or cell death. For exam-
ple, monosodium urate (MSU), calcium pyrophosphate dihydrate
(CPPD) (41), cholesterol crystals (42), amyloid β (80), fatty acids
(47), and mtDNA (48) have all been reported to activate NLRP3.
Microbial NLRP3 agonists have also been identified. NLRP3 senses
bacteria, viruses, fungi, and parasites themselves or virulence fac-
tors such as pore-forming toxins. The list of pathogens detected by
NLRP3 includes Staphylococcus aureus,L. monocytogenes,Klebsiella
pneumoniae, Neisseria gonorrhoeae, E. coli, Porphyromonas gingi-
valis, S. flexneri, Chlamydia spp., the influenza A virus, Aspergillus,
and more recently, Leishmania (Table 1).
NLRC4 AND Naip5
IPAF (also known as NLRC4) is present in the cytosol of myeloid
cells, where it controls the activation of caspase-1 and IL-1β pro-
cessing in response to the presence of intracellular flagellin. NLRC4
directly binds to cytosolic flagellin, an event that promotes its
oligomerization through the nucleotide-binding domain (NBD)
and winged-helix domain (WHD) in the presence of adenosine
diphosphate (ADP) (81). The importance of IPAF-dependent
activation of caspase-1 has been highlighted in infection mod-
els in vitro using Salmonella typhimurium, S. flexneri, Legionella
pneumophila, and P. aeruginosa (66, 70, 74). In such experiments,
IPAF-deficient macrophages were impaired in their ability to acti-
vate caspase-1 and secrete IL-1β and IL-18. Macrophages from
IPAF-deficient mice infected with S. typhimurium have also been
shown to be more resistant to cell death. Indeed, activation of
NLRC4 leads to rapid cell death, a feature that differentiates IPAF
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Table 1 | NLR proteins involved in autophagy and their activators.
NLR protein Activator Reference
Nod1 (NLRC1) FK156 (d-lactyl-l-Ala-γ-Glu-meso-DAP) Uehara et al. (10) and Magalhaes et al. (11)
FK565 (Heptanoly) Uehara et al. (10)
Meso-lanthionine, meso-DAP Uehara et al. (12)
iEDAP (γ-d-Glu-meso-DAP) Girardin et al. (159) and Chamaillard et al. (9)
TriDAP (l-Ala-γ-d-Glu-meso-DAP) Girardin et al. (4)
TCT (GlcNAc-(anhydro) MurNAc-l-Ala-γ-d-Glu-mesoDAP-d-Ala) Magalhaes et al. (11)
Bacillus species Hasegawa et al. (13)
L. pneumophila Hasegawa et al. (13)
S. typhimurium Hasegawa et al. (13) and Le Bourhis et al. (14)
H. pylori Viala et al. (15)
Pseudomonas species Travassos et al. (7)
Chlamydia species Kavathas et al. (16), Buchholz and Stephens (17), Welter-Stahl et al.
(18) and Opitz (19)
L. monocytogenes Park et al. (20), Kim et al. (21) and Opitz et al. (22)
E. coli Kim et al. (23)
S. flexneri Girardin et al. (24) and Carneiro et al. (25)
C. jejuni Al-Sayeqh et al. (26) and Zilbauer et al. (27)
T. cruzi Silva et al. (28)
Nod2 (NLRC2) Muramyldipeptide (MurNAc-l-Ala-d-isoGln) Girardin et al. (8) and Inohara et al. (5)
M-TriLys (Mur-NAc-l-Ala-d-Glu-Lys) Girardin et al. (4)
Respiratory syncytial virus (RSV) Sabbah et al. (29)
Bacillus species Hasegawa et al. (13)
Lactobacillus species Hasegawa et al. (13)
Corynebacterium xerosis Hasegawa et al. (13)
E. coli Hasegawa et al. (13)
Pseudomonas species Hasegawa et al. (13)
M. tuberculosis Juárez et al. (30), Ferwerda et al. (31) and Divangahi et al. (32)
S. pneumoniae Travassos et al. (33) and Liu et al. (34)
C. jejuni Al-Sayeqh et al. (26)
S. flexneri Kufer et al. (35)
S. typhimurium Keestra et al. (36) and Hisamatsu et al. (37)
L. monocytogenes Kobayashi et al. (38)
Nalp3 (NLRP3) Muramyldipeptide (MurNAc-l-Ala-d-isoGln) Martinon et al. (39)
Bacterial RNA Kanneganti et al. (40)
Imidazoquinoline compounds Kanneganti et al. (40)
MSU (monosodium urate) Martinon et al. (41)
CPPD (calcium pyrophosphate dihydrate) Martinon et al. (41)
Cholesterol crystals Duewell et al. (42)
Silica Hornung et al. (43), Kuroda et al. (44) and Cassel et al. (45)
Aluminum salts Hornung et al. (43) and Kuroda et al. (44)
Amyloid-beta Halle et al. (46)
Fatty acids Wen et al. (47)
Mitochondrial DNA Nakahira et al. (48) and Shimada et al. (49)
Aerolysin Gurcel et al. (50)
Maitotoxin Mariathasan et al. (51)
ATP Mariathasan et al. (51)
Nigericin Mariathasan et al. (51)
S. aureus Craven et al. (52)
L. monocytogenes Kim et al. (53)
P. gingivalis Huang et al. (54)
(Continued)
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Table 1 | Continued
NLR protein Activator Reference
Chlamydia species Abdul-Sater et al. (55) and He et al. (56)
Influenza A virus Thomas et al. (57) and Allen et al. (58)
Aspergillus Saïd-Sadier et al. (59)
Leishmania Lima-Junior et al. (60)
ROS Zhou et al. (61)
IPAF (NLRC4) Cytosolic flagellin Franchi et al. (62)
L. pneumophila Case et al. (63), Vinzing et al. (64) and Coers et al. (65)
S. typhimurium Mariathasan et al. (66), Broz et al. (67) and Miao et al. (68)
S. flexneri Suzuki et al. (69)
P. aeruginosa Cohen and Prince (70), Sutterwala et al. (71) and Franchi et al. (72)
Naip5 Cytosolic flagellin (in cooperation with IPAF) Zamboni et al. (73)
L. pneumophila Lightfield et al. (74) and Zamboni et al. (73)
from the other NLRs (66). Another pathogen whose detection
induces cell death through IPAF is L. pneumophila. However, in
this case, another NLR protein, Naip5 (also known as Birc1e), is
required. Both Naip5 and IPAF have been reported to physically
interact, but the role of Naip5 in caspase-1 activation remains to be
fully elucidated, as A/J mice (mice with a mutation that results in
a non-functional Naip5) are able to secrete IL-1β following infec-
tion with S. typhimurium, P. aeruginosa, and L. monocytogenes (66,
71, 73) (Table 1).
Shigella flexneri also triggers IPAF-dependent activation of
caspase-1 and secretion of IL-1β. These data are intriguing consid-
ering that S. flexneri is a non-flagellated bacterium, suggesting that
other factors are able to activate IPAF (69). Indeed, more recent
studies revealed that P. aeruginosa strains lacking flagellin are still
able to induce secretion of IL-1β through NLRC4 (71) (Table 1).
Although the importance of IPAF in cytosolic flagella sensing
is broadly recognized, it has been demonstrated that flagellin-
dependent responses may occur in the absence of IPAF. Recently,
a new pathway was reported in which macrophage stimulation
with flagellin leads to cell death in a cathepsin B and D-dependent
manner even in IPAF-deficient cells. It has yet to be determined
whether a new flagellin sensor is involved in such events (82).
NLRX1
In contrast to the huge amount of data regarding other NLR pro-
teins, little is known about the biological function of NLRX1.
This protein is highly conserved among species and has sequence
homology with Nod3. Unlike other NLRCs, NLRX1 has no CARD
in its N-terminal portion but does have a putative mitochondrial-
targeting sequence (83). Indeed, what we know about NLRX1
is derived from its mitochondrial localization, even though its
precise localization inside this organelle is still a matter of
debate. Studies from two independent groups report conflicting
results; while Arnoult et al. claimed that NLRX1 is located in
the mitochondrial matrix, Moore et al. proposed that the pro-
tein localizes to the outer mitochondrial membrane (84, 85).
There are also discrepancies concerning the attributed func-
tion of NLRX1. Initial results from Tattoli et al. reported that
NLRX1 amplifies NF-κB and JNK through the production of
ROS. Opposing results from Moore et al. suggest that NLRX1
functions as a brake on innate immune pathways by inhibit-
ing mitochondrial antiviral signaling (MAVS)-dependent NF-κB
and IFN-β production upon poly I:C stimulation in vitro (85,
86). Further studies are required to clarify of the function of
NLRX1.
NLRP4
Very little is known about NLRP4, a 113-kDa protein also known as
Nalp4 or PYPAF4. This protein is expressed in tissues as diverse as
testis, oocytes, spleen, placenta, thymus, kidney, and lung. NLRP4
has been recently reported as a negative regulator of type I IFN
signaling by targeting tank binding kinase-1 (TBK-1) for degrada-
tion as well as of TNF-α and IL-1β by inhibiting NF-κB activation
by interacting with IKKα (87, 88).
AUTOPHAGY
The term autophagy (meaning “self-eating”) was first introduced
at the CIBA Foundation Symposium on Lysosomes in 1963 by
cell biologist Christian de Duve, who also discovered lysosomes
in 1955 (Nobel Prize in Physiology in 1974) and coined sev-
eral other terms currently used today, such as “endocytosis” and
“exocytosis.” Autophagy was first characterized by the presence
of single- or double-membrane vesicles harboring cytoplasmic
content in different stages of degradation – the autophagosomes.
At that time, de Duve and others considered autophagy to be a
non-selective degradation pathway. However, under specific cir-
cumstances, autophagy is highly specific and plays essential roles
in maintaining homeostasis. For a complete historical perspective
on autophagy and its importance in different pathologies, please
refer Ref. (89–91).
Autophagy is a highly conserved cellular homeostatic process
in which long-lived proteins, damaged organelles, or parts of
the cytosol are delivered to lysosomes for degradation and recy-
cling of functional blocks for anabolic reactions, especially dur-
ing nutrient shortages. Indeed, for years, autophagy was con-
sidered a mere response to nutritional stress given that initial
observations demonstrated that glucagon or amino acid depriva-
tion triggered the formation of autophagosomes while exogenous
amino acids supplementation inhibited autophagy and protein
breakdown (92).
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THE MACHINERY OF AUTOPHAGOSOME BIOGENESIS
So far, three types of autophagy have been described, chaperone-
mediated autophagy (CMA), microautophagy, and macroau-
tophagy (hereafter, autophagy) (93). The hallmark of autophagy
is the generation of autophagosomes. This process occurs in a
stepwise manner controlled by over 30 Atg genes that were ini-
tially identified in yeast species. Interestingly, most of these genes
have mammalian orthologs or paralogs with high structural and
functional similarities. Briefly, the process starts with the forma-
tion of a cup-shaped membrane or phagophore. Once formed,
the membrane elongates and selectively and/or non-selectively
enwraps the cargo (i.e., the cytosolic target), eventually seal-
ing, completing the formation of the autophagosome. The outer
membrane of the autophagosome the fuses with a lysosome mem-
brane, forming the autolysosome, where all the degradation steps
of the autophagic response take place (Figure 1). The source
of the autophagosomal membrane is still a matter of debate.
Various studies have proposed the plasma membrane, the endo-
plasmic reticulum or the outer mitochondrial membrane as the
source (92).
THE CORE AUTOPHAGY PATHWAY
At the molecular level, the number of proteins implicated in the
control of autophagy is still expanding and linking autophagy
with several other pathways. Here, we focus on the core of the
autophagic pathway and its links to NLR signaling. For autophago-
somes formation, the following two ubiquitin-like (UBL) systems
are required: (i) in the Atg12 conjugation system, Atg5 and Atg12
form complexes through the covalent binding of Atg12 to the
C-terminal glycine of ATG5 in UBL reactions involving Atg7
and Atg10. Atg16L1, a scaffold protein, is then conjugated to
the Atg5-Atg12 complex by binding to the N-terminus of Atg5.
The Atg5-Atg12-Atg16L1 complex multimerizes, forming large
800 kDa complexes that are found in the cytosol and in the forming
membrane. It has been shown that the Atg16L1 complex acts as a
E3-like enzyme, targeting microtubule-associated protein 1 light
chain 3 (LC3) to its membrane site of lipid conjugation. (ii) The
Atg8 conjugation system is crucial for inducing modifications in
LC3. Under normal conditions, LC3 has a diffuse cytosolic distri-
bution pattern. LC3 is cleaved at its C-terminus by Atg4, a cysteine
protease, and undergoes UBL modifications by the E1-like enzyme,
Atg7, and the E2-like enzyme, Atg3, to form LC3-I (94). Dur-
ing the induction of autophagy, the C-terminal carboxyl group of
LC3-I is eventually conjugated with phosphatidylethanolamine to
form LC3-II, which is found exclusively on the autophagosomal
membrane. For this reason, LC3-II is widely used as an autophagy
marker (95).
The Atg proteins, the autophagic machinery, seem to
require other proteins to form autophagosomes. Similar to
the Atg1-Atg13-Atg17 complex found in yeast, the Unc-51-like
kinase (ULK1), focal adhesion kinase family integrating protein
(FIP2000), and Atg13 proteins were described to colocalize at the
nascent isolation membrane after induction of autophagy in mam-
malian cells (96, 97). Another protein that was shown to participate
in autophagy is Atg9. Studies in mammals have demonstrated that
Atg9 is essential for autophagosome formation as it associates
with the trans-Golgi, endosomes, LC3, and Rab GTPases (Rab7
and Rab9) and redistributes following the induction of autophagy
(92). In Figure 1, we summarize the main proteins and all the steps
that are part of the formation of autophagosomes.
FIGURE 1 |The steps of autophagosome formation. Macroautophagy
begins with the formation of a cup-shaped structure called a phagophore
as a consequence of the activity of the ULK1/2 complex. In the sequence,
the ATG5-ATG12-ATG16L1 complex, Class III PtdIns3K, ATG9, and LC3
assist in the formation of the autophagosome. Autophagosomes
completely wrap their cargo and fuse with endosomes (forming an
amphisome, which will later fuse with lysosomes) or directly with
lysosomes, forming an autolysosome. Upon fusion, the cargo is degraded
by lysosomal hydrolases and exported back to the cytosol to be used by
the cell.
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Interestingly, it has been proposed that autophagy may occur
even in the absence of ATG proteins in both insects and mammals.
However, the conditions that trigger ATG-independent autophagy
and whether this type of autophagy is particular to some cell types
remain to be determined (98, 99).
CONTROL OF AUTOPHAGY
The vast number of pathways that connect to autophagy gives
rise to an intricate network that makes our understanding of
autophagy regulation far from complete. A major breakthrough in
understanding autophagy regulation was made when the target of
rapamycin (TOR) in yeast and mammals was discovered, implicat-
ing the involvement of phosphatidylinositol kinase-related kinases
in the process (100–102). Both pathways are linked by the key
serine/threonine kinase Akt and are known to participate in sev-
eral cellular responses such as proliferation and metabolic adap-
tation (92). Activators of phosphatidylinositol-3 kinase (PI3K)
range from cytokines to TLR ligands. After receptor activation,
phosphatidylinositol-4,5-biphosphate is phosphorylated by class-
I PI3K, activating Akt. mTOR complexes are effectors downstream
of Akt and integrate a myriad of cellular signals, especially those
related to protein synthesis and translation (103–106). Under opti-
mal nutrient conditions, autophagy is negatively regulated by Akt
and mTOR (107). This negative regulation of autophagy by mTOR
has been recently shown to require inhibition of ULK kinase-
complex activity through its phosphorylation (108). At least in
yeast, ULK1 seems to regulate autophagy not only by inhibiting
mTOR but also by interacting with Atg8 (109). It remains to be
tested whether these findings also apply in mammals. Another
mechanism involved in the control of mTOR activation is the
recruitment of TNF receptor-associated factor 6 (TRAF6) to the
lysosome by p62, where it drives the polyubiquitination of mTOR
during optimal nutrient conditions (110).
Upon the induction of autophagy, vacuolar protein sorting 34
(Vps34), a class III phosphatidylinositol-3-phosphate (PtdIns3P)
kinase (PI3K) enzyme, specifically phosphorylates phosphatidyli-
nositol and is implicated in trafficking, nutrient sensing, and
autophagy (111, 112). In yeast, the role of PtdIns3P seems to go
beyond autophagosomal membrane elongation. It has been pro-
posed that the levels of PtdIns3P in the phagophore assembly site
(PAS) regulate autophagosome turnover due to the accumulation
of ATG proteins in the membrane (113). Other important play-
ers in autophagosome formation are Vps15, beclin-1, ultraviolet
radiation resistance associated gene (UVRAG), and ambra1, which
together form a multiprotein complex with Vps34 that is necessary
for the initial steps in autophagosome formation. For a complete
view of the autophagy pathway, see the review by Boya et al. (114).
AUTOPHAGY AND IMMUNITY TO INFECTIONS
The contamination of the cytosolic compartment with invasive
pathogens is a major step in the activation of innate immune
defenses. In this regard, autophagy has emerged in recent years as
another component of the innate immune system’s arsenal. Several
microbial agents are recognized by the autophagic machinery, and
their fates can vary from destruction to the creation of a replica-
tive niche. It has been shown that the autophagic machinery can
selectively segregate microbes in the cytosol. The mechanisms by
which such specificity is achieved are not completely understood
but seem to involve both microbial and host factors. Similar to
MAMPs, which themselves were shown to induce autophagosome
formation, toxins secreted by pathogens also induce autophagy
(115). In a landmark paper, Nakagawa et al. demonstrated that
group A Streptococcus (GAS) lacking streptolysin O (SLO) do
not escape from phagocytic vacuoles, and thus, do not activate
autophagic sequestration (116).
Gram-negative bacteria are recognized by the autophagic
machinery as well. For example, S. flexneri uses a type 3 secre-
tion system (T3SS) to deliver effector proteins directly into the
host cell. Ogawa et al. showed that, in epithelial cells, the wild-type
(WT) S. flexneri strain is capable of evading autophagic seques-
tration. This is dependent on the T3SS effector IcsB, as the mutant
strain lacking IcsB is trapped by autophagy. The role of IcsB seems
to be to camouflage the bacterial target molecule (VirG) from
the autophagy machinery (117, 118). Interestingly, these obser-
vations seem to vary depending on cell type, given that in bone
marrow-derived macrophages, no difference in bacteria sequestra-
tion was observed between the WT and IcsB mutant strains (69).
The autophagic machinery apparently relies on redundant strate-
gies to fight Shigella; different mechanisms have been described for
the induction autophagy by this pathogen. In one mechanism, the
phagocytic vacuolar membrane remnants, rather than bacterium
itself, trigger autophagy in response to bacterial invasion (119).
Avoidance of autophagic destruction has also been reported
for other bacteria. The Burkholderia pseudomallei T3SS effec-
tor, BopA, which shares some homology with IcsB, contributes
to bacterial evasion from autophagosome targeting (120). The
Gram-positive bacterium L. monocytogenes is able to invade host
cells, where it finds a replicative niche within the cytosol fol-
lowing autophagosome escape. These events are dependent on
the expression of listeriolysin O (LLO), ActA, and phospholipase
C (121).
However, autophagy can serve as a back-up control mechanism
for bacteria that are able to escape from other defense mechanisms.
For example, after invading the host cell, S. typhimurium resides
within vacuoles called Salmonella-containing vacuoles (SCV). Fol-
lowing SCV damage mediated by its T3SS, S. typhimurium gains
access to the cytosol where autophagy is immediately activated to
confine the bacteria and restrict the infection (122). In the case of
M. tuberculosis, which is known to subvert host cell phagosomal
maturation and survive within macrophages, autophagy induction
via rapamycin or IFN-γ circumvents the phagosomal maturation
blockade, leading to M. tuberculosis elimination (123).
Viral pathogens interact with the autophagic pathway as well.
Herpes simplex virus (HSV) ICP34.5 interacts with beclin-1 and
blocks autophagosome formation (124). In vesicular stomatitis
virus (VSV)-infected DCs, autophagy is essential for the delivery of
viral ligands to endosomes to induce type I IFN production (125).
NLR-MEDIATED AUTOPHAGY AND INFECTION
As mentioned before, the first line of host defense against infec-
tion relies on various families of PRMs. As it became evident that
autophagy is also an innate immune effector mechanism, consid-
erable efforts were made to understand the role of PMRs in the
autophagic response to pathogens.
The first study linking MAMP sensing and autophagy induc-
tion was the work by Xu et al. who showed a role for TLRs in
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autophagy. TLRs are transmembrane proteins that recruit myeloid
differentiation primary response protein 88 (MyD88) and Toll-IL-
1 receptor (TIR) domain-containing adapter-inducing IFN (Trif)
adapter proteins through their TIR domain to initiate downstream
signaling. It was demonstrated that LPS induces autophagy in
a TLR4-p38-RIP1-Trif-dependent manner (126). Later, a report
from Delgado et al. showed that TLR7 could elicit similar responses
upon stimulation of macrophages with ssRNA, and this was also
dependent on the recruitment of MyD88 (127). The balance
between Beclin-1 and Bcl-2 is a major checkpoint in the pathway
for autophagy induction. Shi et al. (128) proposed that MyD88
and Trif both target Beclin-1, resulting in decreased binding to
Bcl-2 and subsequent autophagy activation upon TLR stimula-
tion. MyD88 and interferon-regulatory factors (IRFs) 5 and 7 are
also recruited by mTOR to control cytokine production (128, 129).
Despite increasing evidence showing a role for TLRs in the
induction of autophagy, it remains unclear how the autophagic
machinery is directed to trap an entire microorganism during
infection, especially considering that they are transmembrane pro-
teins. Several bacteria, such as Salmonella, Mycobacterium, and
Listeria, grow within host cells and by doing so can avoid antibody
and cellular dependent defenses. Intracellular PRMs, such as the
NLR family, are known for their essential role as cytosolic sentinels
that can trigger robust cytokine production and inflammation.
However, little was known regarding how these sensors contribute
to the elimination of intracellular invaders. The first evidence
implicating NLRs in autophagy-dependent control of an intra-
cellular infection came from studies using Drosophila as a model.
Yano et al. (130) reported that, upon infection of hemocytes with
L. monocytogenes, Drosophila PGRP-LE detects diaminopimelic
(DAP)-containing PG to trigger autophagy directed against the
bacterium. Consistent with these observations, PGRP-LE null
mutants were more susceptible to infection (130). The recogni-
tion of intracellular PG and subsequent induction of autophagy
seem to be conserved features of the innate immune system.
In 2010, two independent studies reported Nod1- and Nod2-
dependent autophagy upon PG detection. We showed that Nod1
and Nod2 direct autophagy by recruiting ATG16L1 to the plasma
membrane during bacterial entry into the host cell (Figure 1).
Interestingly, the most common mutation in Nod2 associated with
CD, Nod21007fs, results in a protein that fails to recruit ATG16L1
to initiate the formation of autophagosomes, although they still
interact in the cytosol. In another study, Cooney et al. (131) found
that Nod2 induces autophagy in human DCs, increasing bacterial
killing, and antigen presentation. DCs expressing CD-associated
variants displayed lower autophagy and antigen presentation lev-
els upon MDP stimulation. Interestingly, while we demonstrated
that the adaptor protein Rip2 and NF-κB activation is dispensable
for autophagy induction because Rip2-deficient fibroblasts dis-
played similar numbers of S. flexneri targeted to autophagosomes,
Cooney et al. found that Rip2-deficient DCs had reduced levels of
autophagy. The difference in the cell types used could account for
such differences (131, 132).
These studies gained additional relevance as a recent link
between polymorphisms in ATG16L1 and CD was uncovered.
CD and ulcerative colitis (UC) are common presentations of
idiopathic IBD. It is estimated that their prevalence in Cau-
casian individuals reaches 100–150 per 100,000 (133). IBD is the
outcome of combined genetic and non-genetic risk factors, and
recently genome wide association studies (GWAS) have identified
a non-synonymous single nucleotide polymorphism in ATG16L1
(T300A) as one of the most important genetic risk factors for
CD. Studies in which the implications of this polymorphism were
analyzed show that MDP-induced but not canonical autophagy is
impaired in cells of individuals carrying the T300A variant (131,
132). The effect of this polymorphism on the restriction of bacte-
rial growth varies depending on the cellular and bacterial models
used. Epithelial cells expressing the T300A variant show decreased
bacteria-targeted autophagy during infection with S. typhimurium
(134). Monocytes from patients with CD and carrying the T300A
allele infected with M. avium paratuberculosis display no differ-
ence in bacterial growth in comparison to patients with the normal
allele (135). The impact of this variant on cytokine release has also
been evaluated, and again, contradictory findings were observed.
Plantinga et al. (136) reported that upon Nod2 stimulation with
MDP (but not with TLR ligands), PBMCs from healthy volun-
teers carrying the T300A variant secreted increased amounts of
IL-1β (136). In contrast, in another study, the same group demon-
strated that PBMCs with the variant allele do not produce more
IL-1β in comparison to the normal allele upon infection with M.
tuberculosis (137).
Legionella pneumophila, a Gram-negative pathogen of amebae,
is also able to replicate within alveolar macrophages and cause the
pneumonia known as Legionnaire’s disease. Mouse macrophages,
in contrast to human cells, restrict L. pneumophila replication
through the activation of Naip5 and NLRC4 by cytosolic flagellin
and activation of caspase-1 resulting in pyroptosis. In a recent
study, Byrne et al. demonstrated that flagellin recognition by Naip5
and NLRC4 increases autophagosome turnover (138).
NLRX1 has been shown to enhance autophagy. A recent study
demonstrated that NLRX1 enhances autophagy through interac-
tion with the Tu translation elongation factor (TUFM) which,
in turn, interacts with the Atg5-Atg12 complex. It is not clear,
however, how this NLRX1-TUFM-Atg5-Atg12 interaction leads
to increased autophagy. Still, NLRX1 plays an important role as a
pro-autophagic factor during vesicular stomatitis (VSV) infection.
Lei et al. (139) showed decreased viral replication in NLRX1-
deficient fibroblasts, suggesting that autophagy is important for
VSV replication, although a previous work demonstrated that
VSV succumbs to autophagy in a Drosophila model (139, 140).
Of note is the fact that the role of NLRX1 in autophagy varies
among studies using the different NLRX1 knockout mice avail-
able. While Soares et al. and Rebsamen et al. found that the MAVS
pathway is fully functional in their NLRX1-deficient mice, Allen
et al. reported an enhancement in this signaling pathway using
a different NLRX1 knockout mice [the same used by Lei et al.
(139, 141–143)]. It remains to be determined whether the role of
NLRX1 in autophagy is specific to the knockout animals used by
Lei et al. or if it is a general feature of all NLRX1-deficient mice
(Figure 2B).
Finally, in contrast to what was described above, NLRs can
also act as negative regulators of autophagy through mechanisms
that are not yet completely elucidated. Suzuki et al. reported that
NLRC4- and caspase-1-deficient macrophages display increased
targeting of S. flexneri to autophagosomes (69). Similar results
were found in a study analyzing the impact of NLRC4 and NLRP4
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FIGURE 2 |The different means by which pathogens and autophagy
interact and their outcomes. (A) During bacterial invasion, Nod1/2 recruit
ATG16L1 to the bacterial entry site to promote the initiation of
autophagosome (green rectangle) formation, targeting the bacterium. After
enclosing the pathogen, the autophagosome fuses with lysosomes (red
square), giving rise to an autolysosome (yellow rectangle) in which the
content is degraded by lysosomal hydrolases to control bacterial replication in
the cytosol. NLRP4 can interfere in autolysosome formation. (B) In cells with
functional autophagic machinery, damaged mitochondria are targeted to
autophagosomes (green rectangles) avoiding the accumulation of ROS and
limiting inflammation. (C) Cells in which autophagy is impaired accumulate
swollen mitochondria and high levels of ROS, leading to uncontrolled IL-1β
production. Alternatively, damaged mitochondria release mitochondrial DNA
(mtDNA), which is sensed by NLRP3 that, together with ROS, induces the
production of IL-1β. (D) Inflammasome sensors are ubiquitinated and targeted
to autophagosomes (green rectangles) for degradation, limiting the
production of IL-1β. (E) Pro-IL-1β is targeted to autophagosomes (green
rectangles) upon autophagy induction (by rapamycin) to limit the magnitude of
inflammation. (F) NLRX1 associates with ATG16L1 and the ATG5/12 complex
to induce the formation of autophagosomes (green rectangles) targeting VSV,
which later fuse with lysosomes (red square), forming autolysosomes (yellow
rectangles) in which the virus is degraded.
on autophagy, where it was demonstrated that epithelial cells with
both proteins silenced displayed enhanced autophagy. A partial
explanation for these observations is that NLRP4 is part of the
Beclin-1 and C-VPS (a complex consisting of VPS11, VPS16,
VPS18, and Rab7 that controls membrane tethering and fusion of
vacuolar membranes) complexes, which are essential for the bio-
genesis and maturation of autophagosomes, respectively (144).
The elucidation of the precise mechanisms by which NLRP4
exerts its negative effects on autophagy requires further studies
(Figure 2A).
AUTOPHAGY-DEPENDENT CONTROL OF NLR-DEPENDENT
INFLAMMATION
Another function of autophagy seems to be the control of the
magnitude of inflammatory responses (145). In the last few years,
several groups have reported that autophagy blockade by phar-
macological or genetic means leads to increased production of
cytokines by different mechanisms. Two independent studies have
shown that ATG5-deficient fibroblasts produce significantly more
IFN-I and IL-6 then WT cells during viral infection. The mech-
anisms likely involve the interaction between ATG12-ATG5 com-
plexes with IPS-1, RIG-I, and MDA-5 and accumulation of dam-
aged mitochondria in the autophagy-deficient cells, as discussed
below (146, 147).
AUTOPHAGY AND INFLAMMASOMES
A ROLE FOR ROS
As discussed above, the cells deficient in ATG genes produce
increased levels of pro-inflammatory cytokines (146, 147). Tal et
al. (147) demonstrated a vital role of autophagy in the removal of
damaged mitochondria (mitophagy), and thus, in cell homeosta-
sis. Cells with defects in autophagy, such as Atg5-deficient cells,
accumulate damaged mitochondria, and consequently present
increased levels of ROS. This in turn results in the enhancement
of the levels of IFNα and IL-6 production upon infection with
VSV. In addition, the authors show that by using the antioxidants
N -acetyl-L-cysteine (NAC) and propyl-gallate (PG) during VSV
infection, they were able to revert the increase in cytokine pro-
duction. The removal of damaged mitochondria can be regulated
by adapter proteins that participate in NLR-activating pathways.
For example, besides its well-known and crucial role linking Nod1
and Nod2 sensing to NF-κB activation, Rip2 has also been impli-
cated in mitophagy. In a recent study, Lupfer et al. showed that
Rip2 regulates mitophagy through ULK1 to keep ROS at basal lev-
els. Genetic deletion of Rip2 leads to the accumulation of ROS
and significantly higher levels of IL-18 and IFN-γ upon influenza
infection (148) (Figure 2C).
Among all the cytokines that have been studied, IL-1β seems to
be the cytokine whose production is most dramatically affected by
autophagy. Processing and activation of pro-IL-1β into its active
form depends on the assembly of inflammasomes. Increased ROS
levels seem to be a prerequisite for inflammasome activation. The
manipulation of autophagy by pharmacological or genetic means
has a profound impact on IL-1β production and secretion dur-
ing infection or LPS treatment. Indeed, the use of the autophagy
inhibitor 3-methyladenine (3-MA), deletion of LC3B or ATG16L1,
silencing of Beclin-1 or dominant negative forms of the cysteine
protease ATG4B all lead to remarkably higher amounts of IL-1β
(48, 149–151). The first evidence to show that autophagy can mod-
ulate IL-1β production surfaced in 2008 with the work of Saitoh
et al. These authors reported that macrophages from ATG16L1-
deficient mice produced much higher levels of IL-1β after LPS
exposure and that this was not due to defects in the genera-
tion of pro-IL-1β and pro-caspase-1. These authors proposed a
model in which TRIF and loss of K+ and ROS are required for the
activation of inflammasomes, and subsequently, IL-1β processing
(150). However, it remains to be shown that these observations
were not due to defective mitophagy. Further studies not only
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confirmed but expanded the evidence for the requirement of func-
tional autophagy for the maintenance of basal levels of ROS, and
subsequently, for the control of inflammasome activation. In an
elegant study, Nakahira et al. dissected the role of autophagy in
the activation of the NLRP3 inflammasome. In a series of exper-
iments in which autophagy was inhibited either by deletion of
LC3B or by heterozygous deletion of Beclin-1, a robust increase in
IL-1β processing and release was observed following stimulation
with LPS plus ATP. According to the authors, these stimuli led to
swollen mitochondria and the release of its DNA (mtDNA). In
ρ0 J774A.1 macrophages, the release of mtDNA into the cytosol
is blocked, and IL-1β secretion is impaired. Similar results were
obtained when cells were treated with DNAse I. Interestingly,
the production of ROS and consequent activation of the inflam-
masome were dependent on the presence of cytosolic mtDNA.
Altogether, the results from this study delineate a model in which
LPS plus ATP induce mitochondrial damage, ROS production, and
NLRP3-dependent release of mtDNA into the cytosol, resulting in
the activation of caspase-1 and release of IL-1β (48). The findings
reported by Nakahira et al. were partially contradicted by a more
recent study that suggests that ATP actually induces the release of
oxidized mtDNA, which in turn binds to NLRP3 to induce IL-
1β production. Oxidized mtDNA was not detected in the cytosol
of NLPR3-deficient macrophages. According to the authors, this
could be explained by the fact that unbound oxidized mtDNA is
rapidly degraded, but this later observation still lacks experimen-
tal confirmation (49) (Figure 2D). It is important to note that the
idea of ROS as an activator of NLPR3 inflammasomes was chal-
lenged by a study demonstrating that ROS is key for priming of
NLRP3 but not for its activation. One way or another, it is clear
that ROS is necessary for IL-1β production (152).
The source of ROS required for inflammasome activation is also
a matter of debate. Initial reports suggested that nicotinamide din-
ucleotide phosphate (NADPH) oxidases were the main source for
inflammasome activation (153). The NADPH complex comprises
the membrane-bound gp91phox and p22phox glycoproteins and the
cytosolic components p47phox and p67phox. Patients with chronic
granulomatous disease (CGD) can have mutations in any of the
NADPH oxidases and as a result present defective phagocytes
because their cells have impaired capacity to generate superoxide
anion and its metabolites, hydrogen peroxide, the hydroxyl anion,
and hypohalous acid (154). Meissner et al. reported that in mono-
cytes from CGD patients with mutations in gp91phox, p22phox,
and p47phox, stimulation with LPS plus ATP led to the activation
of caspase-1 and secretion of mature IL-1β (155). Furthermore,
monocytes from CGD patients presented elevated IL-1β levels in
comparison to monocytes from healthy controls (154). These find-
ings challenged the notion that NADPH oxidases are the source
of ROS necessary to induce inflammasome activation. This ques-
tion was apparently clarified by the work of Zhou et al. which
demonstrated that ROS generated by dysfunctional mitochondria
[mtROS, achieved by either by treating cells with the complex
I inhibitor, rotenone, or silencing of the voltage-dependent anion
channel (VDAC)] activates the Nlrp3 inflammasome. The require-
ment of mtROS for activation of the inflammasome seems to be
specific for Nlrp3 because VDAC1 silencing did not influence
activation of NLRC4 of AIM2 inflammasomes. Once again, the
crucial role of autophagy in clearing damaged mitochondria was
demonstrated in the work of Zhou et al. in which 3-MA treatment
or beclin-1 or Atg5 silencing resulted in ROS accumulation and
inflammasome activation (61).
As already mentioned, mutations in NLR genes are associated
with increased risk for inflammatory diseases. Auto-activation
of the NLRP3 inflammasome has been linked to several auto-
somal dominant cryopyrinopathies or cryopyrin-associated peri-
odic fever syndromes (CAPS), such as familial cold-induced
autoinflammatory syndrome (FCAS), Muckle–Wells syndrome
(MWS), and neonatal onset multisystem inflammatory disorder
or chronic infantile neurologic cutaneous and articular syndrome
(NOMID/CINCA) (156). These syndromes, despite their different
names, represent a continuum of disease severity where FCAS is
the mildest and NOMID/CINCA the most severe. These cryopy-
rinopathies are associated with periodic fever, rashes, arthralgia,
and conjunctivitis, and the aberrant production of IL-1β is the
most prominent feature related to all these manifestations (6).
The increasing incidence of T2D has become a global health
burden. TD2 has been associated with low-grade inflammation
that leads to insulin resistance. In this context, IL-1β is one of
the main cytokines implicated in T2D, mediating the destruc-
tion of beta cells and resulting in insulin resistance in cells that
were initially sensitive to the hormone. A high-fat diet (HFD)
is one of the factors associated with T2D. Indeed, T2D patients
display augmented levels of free fatty acids in the serum. In a
recent study, Wen et al. demonstrated in a bone marrow-derived
model that palmitate, an abundant saturated fatty acid in the
plasma, inhibits AMP-activated protein kinase (AMPK), leading
to defective autophagy, and thus, ROS accumulation. These events
contribute to the elevation of IL-1β production and impairment
of insulin signaling in vitro (47).
A recent report showed that autophagy is involved not only
in IL-1β production but also in its secretion. Macrophages from
Atg5 conditional knockout mice secreted significantly more IL-1β
during the induction of autophagy triggered by starvation. These
observations need further confirmation (157).
A ROLE FOR UBIQUITIN
As in many aspects of its biology, autophagy has ambiguous roles
in regulating inflammasome activation and acts both as a positive
and negative regulator depending on the experimental model.
In a recent study, Harris et al. provided experimental evi-
dence that autophagy controls inflammasomes by targeting its
components to autophagosomes. These authors showed that pro-
IL-1β is delivered to autophagosomes after TLR stimulation.
Upon autophagy induction by rapamycin treatment, pro-IL-1β
is degraded, limiting the amount available for the processing and
secretion of IL-1β (149) (Figure 2E).
One mechanism underlying the targeting of inflammasome
proteins to autophagosomes seems to be ubiquitination. In a
recent study by Shi et al. it was demonstrated that inflamma-
somes containing ASC are directed to autophagosomes during
NLRP3 or AIM2 activation in primary macrophages. They also
provided evidence that beclin-1 and p62 are involved in tar-
geting ASC to autophagosomes after it is K63 ubiquitination.
The results presented suggest that by using its separate UBA
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and LIR domains, p62/SQTM1 bridges ASC K623 ubiquitina-
tion, and autophagy-dependent degradation (151). In addition
to ASC, NLRP3 is also ubiquitinated in a mtDNA-, ROS-, and
ATP-dependent manner, but its delivery into autophagosomes has
not yet been demonstrated (158) (Figure 2F).
CONCLUDING REMARKS
The NLR and autophagy fields are two exciting research areas in
biology with many unanswered questions related to the precise
mechanisms that coordinate the “talk” between NLR proteins and
autophagy. It will be interesting to discover in more detail whether
autophagy modulation can be used to control NLR-dependent
immune pathways to improve therapeutic strategies for inflam-
matory and infectious diseases. In light of the recent findings that
connect autophagy and inflammasome regulation, it remains to
be determined whether alterations in autophagy could explain,
at least in part, the dysregulated production of IL-1β in NLRP3-
associated cryopyrinopathies. We believe that in the near future,
some of the findings discussed in the present review have the
potential to be translated into new therapeutic strategies that can
be applied in daily medical practice.
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